568513-U

Discovery^® HS C18 (5 µm) HPLC Columns

L × I.D. 25 cm × 4 mm, HPLC Column

• Sinónimos: Discovery RP18 HPLC Column
• Código UNSPSC: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

Propiedades

• Product Name: Columna para HPLC Discovery^® HS C18, 5 μm particle size, L × I.D. 25 cm × 4 mm
• Materiales: stainless steel column
• Nivel de calidad: 100
• Agency: suitable for USP L1
• Línea del producto: Discovery^®
• Características: endcapped
• fabricante / nombre comercial: Discovery^®
• envase: 1 ea of
• Extensión del etiquetado: 20% Carbon loading
• Parámetros: ≤70 °C temp. range; 400 bar pressure (5801 psi)
• técnicas: HPLC: suitable; LC/MS: suitable
• L × D.I.: 25 cm × 4 mm
• superficie: 300 m²/g
• cobertura de la superficie: 3.2 μmol/m²
• impurezas: <10 ppm metals
• Matriz: silica gel, high purity, spherical particle platform; fully porous particle
• grupo activo de la matriz: C18 (octadecyl) phase
• tamaño de partícula: 5 μm
• tamaño de poro: 120 Å
• Intervalo de pH operativo: 2-8
• aplicaciones: food and beverages
• técnica de separación: reversed phase

Descripción

Aplicación

• A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This research developed a robust RP-HPLC method for the quantitative analysis of molnupiravir, a COVID-19 therapeutic, utilizing nanoformulations. The study highlights the method′s stability and effectiveness in permeability studies, demonstrating its potential in pharmaceutical analysis (Reçber et al., 2022).


• Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: The study developed and validated an HPLC-UV method for analyzing terizidone in plasma, essential for pharmacokinetic studies in patients with drug-resistant tuberculosis. The method′s reliability supports its use in clinical and pharmacological research (Mulubwa and Mugabo, 2018).


• Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: This research focuses on optimizing a liquid chromatography method to quantify doxorubicin in plasma and urine. It is crucial for pharmacokinetic, biomedical, and drug monitoring studies, ensuring accurate and precise therapeutic monitoring (Maliszewska et al., 2018).


• Universal efavirenz determination in transport study, rat placenta perfusion and placenta lysate by HPLC-UV.: This study introduces a universal HPLC-UV method for determining efavirenz in various biological matrices, including transport studies, rat placenta perfusion, and lysate. It is significant for pharmacokinetic and drug distribution research (Zelena et al., 2017).

Características y beneficios

• Stable, low bleed for LC-MS applications
• Scalable from analytical to preparatory
• Highly stable to ensure excellent run-to-run and lot-to-lot repducibility
• Higher hydrophobicity for better resolution of difficult analytes

   

Productos recomendados

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Información legal

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany